The mystery of angiographically silent macular oedema due to taxanes

International Ophthalmology

Volumn 32, Issue 3, 2012, Pages 299-304

  Kuznetcova, Tatiana I ^a,b   Cech, Petr ^c   Herbort, Carl P ^a,d  

^a Centre for Ophthalmic Specialised Care COS   (Switzerland)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^c Centre de Chimiothérapie Anti Cancéreuse CCAC   (Switzerland)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cystoid macular oedema; Fluorescein angiography; Indocynine green angiography; Optical coherence tomography; Paclitaxel; Taxane drugs

Indexed keywords

ACETAZOLAMIDE; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; INDOMETACIN; PACLITAXEL; PREDNISOLONE ACETATE;

ADULT; ARTICLE; BLURRED VISION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CONVALESCENCE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA CYSTOID EDEMA; RETINA MACULA LUTEA; TISSUE STRUCTURE; VISUAL ACUITY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; COLORING AGENTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; MACULAR EDEMA; MIDDLE AGED; PACLITAXEL; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84864281078     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-012-9558-9     Document Type: Article

References (15)

1. Crown J, Leary MO, Ooi WS (2004) Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9:24-32 (Pubitemid 38747840)
2. Eisner A, Luoh SW (2011) Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res 36:867-885
3. Teitelbaum BA, Tresley DJ (2003) Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 80:277-279 (Pubitemid 36523527)
4. Behar A, Lauraine EP, Maurel A, Brun MD, Lagrue G, Chauvin FF, Oulid-Aissa D, Hille D (1997) The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 43: 653-658 (Pubitemid 27283577)
5. Semb KA, Aamdal S, Oian P (1998) Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16: 3426-3432 (Pubitemid 28481642)
6. Smith SV, Matthew BA, Benz S, BrownDM(2008) Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol 126:1605-1606
7. Joshi MM, Garretson BR (2007) Paclitaxel maculopathy. Arch Ophthalmol 125:709-710 (Pubitemid 46762738)
8. Bringmann A, Reichenbach A, Wiedemann P (2004) Pathomechanisms of cystoid macular edema. Ophthalmic Res 36:241-249 (Pubitemid 39664117)
9. Marmor MF (1999) Mechanisms of fluid accumulation in retinal edema. Doc Ophthalmol 97:239-249
10. Telander DG, Sarraf D (2007) Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 22:151-153 (Pubitemid 47346970)
11. Karakashian S, Bayliff CD (2001) Niacin-induced cystoid macular edema. CJHP 54:35-36 (Pubitemid 33712585)
12. Dajani HM, Lauer AK (2006) Optical coherence tomography findings in niacin maculopathy. Can J Ophthalmol 41:197-200
13. Michaud LB, Valero V, Hortobagyi G (2000) Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 23:401-428
14. Mitchison TJ (1992) Compare and contrast actin filaments and microtubules. Mol Biol Cell 3:1309-1315 (Pubitemid 23091459)
15. Burnside B, Bost-Usinger L (1998) The retinal pigment epithelium cytoskeleton. In: Marmor MF, Wolfensberger TJ (eds) The retinal pigment epithelium. Oxford University Press, New York, pp 41-67